iFAST Diagnostics

iFAST Diagnostics is pioneering a new era in antimicrobial resistance (AMR) testing with its rapid Antimicrobial Susceptibility Testing (AST) platform.

The UK-based healthtech startup leverages advanced microfluidics technology to analyse bacterial samples and deliver accurate, actionable results in under three hours — a major breakthrough compared to the current 48-72 hours required by traditional methods. This accelerated testing process empowers clinicians to identify the most effective antibiotics for patients quickly, improving outcomes and saving lives, particularly in critical conditions like sepsis and drug-resistant infections.

Founded in 2022 by a team of experienced scientists and innovators, iFAST is on track to launch its technology in the UK in early 2025, with plans for further expansion into the US and Europe. With strong backing from investors including the first NHS-anchored venture fund and Raw Ventures, iFAST is poised to become a leader in the global fight against antimicrobial resistance, offering a solution that enhances both patient care and healthcare efficiency.